Mechanisms for oral absorption enhancement of drugs by nanocrystals

被引:52
作者
Liu, Jiali [1 ]
Tu, Liangxing [1 ]
Cheng, Meng [1 ]
Feng, Jianfang [1 ,2 ]
Jin, Yi [1 ]
机构
[1] Jiangxi Univ Tradit Chinese Med, Natl Pharmaceut Engn Ctr Solid Preparat Chinese H, Nanchang 330006, Jiangxi, Peoples R China
[2] Guangxi Univ Chinese Med, Sch Pharm, Nanning 530200, Peoples R China
基金
中国国家自然科学基金;
关键词
Nanocrystals; Oral; Absorption; Mechanism; Transport; POORLY SOLUBLE DRUGS; IN-VITRO; DISSOLUTION RATE; PARTICLE-SIZE; PACLITAXEL NANOCRYSTALS; BIOAVAILABILITY ENHANCEMENT; PHYSICOCHEMICAL PROPERTIES; CARBAMAZEPINE POLYMORPHS; GASTROINTESTINAL MUCUS; CHITOSAN NANOPARTICLES;
D O I
10.1016/j.jddst.2020.101607
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Currently, numerous new compounds suffer from poor water solubility, hindering their oral absorption from the gastrointestinal tract and thereby limiting their clinical application. Nanocrystal technology, with more than 10 products on the market, is one of the favored pharmaceutical technologies for the enhancement of oral bioavailability. However, this technology has a limited ability of bioavailability enhancement for several drugs; therefore, a good understanding about the absorption mechanisms of nanocrystals in the gastrointestinal tract is urgently needed. In this review, the mechanisms of nanocrystals for improving the bioavailability of poorly soluble drugs were summarized from four aspects: enhanced solubility and dissolution rate, enhanced interaction with mucus layer, enhanced transport across the intestinal membrane and enhanced absorption by stabilizers. In addition, the factors that impact the absorption of nanocrystals were also reviewed. We believe that this paper will help scientists understand the in vivo performance of nanocrystals in the gastrointestinal tract and design novel strategies for further improving the bioavailability of nanocrystals.
引用
收藏
页数:11
相关论文
共 118 条
[1]   EVALUATION OF SOLUBILIZERS IN THE DRUG-RELEASE TESTING OF HYDROPHILIC MATRIX EXTENDED-RELEASE TABLETS OF FELODIPINE [J].
ABRAHAMSSON, B ;
JOHANSSON, D ;
TORSTENSSON, A ;
WINGSTRAND, K .
PHARMACEUTICAL RESEARCH, 1994, 11 (08) :1093-1097
[2]   Bioavailability of nanoparticles in nutrient and nutraceutical delivery [J].
Acosta, Edgar .
CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, 2009, 14 (01) :3-15
[3]   Chitosan-coated diacerein nanosuspensions as a platform for enhancing bioavailability and lowering side effects: preparation, characterization, and ex vivo/in vivo evaluation [J].
Allam, Ahmed N. ;
Hamdallah, Herif I. ;
Abdallah, Ossama Y. .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2017, 12 :4733-4745
[4]   Second generation of drug nanocrystals for delivery of poorly soluble drugs: smartCrystal technology [J].
Mueller, Rainer H. ;
Keck, Cornelia M. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 34 (01) :S20-S21
[5]   A review of drug solubility in human intestinal fluids: Implications for the prediction of oral absorption [J].
Augustijns, Patrick ;
Wuyts, Benjamin ;
Hens, Bart ;
Annaert, Pieter ;
Butler, James ;
Brouwers, Joachim .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 57 :322-332
[6]  
Aziz F., 2013, MATH PROBL ENG, V2013, P1
[7]  
Bogataj M, 2003, BIOL PHARM BULL, V26, P743
[8]   Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs [J].
Böhm, BHL ;
Müller, RH .
PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1999, 2 (08) :336-339
[9]   Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery [J].
Brough, Chris ;
Williams, R. O., III .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 453 (01) :157-166
[10]   Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs [J].
Censi, Roberta ;
Di Martino, Piera .
MOLECULES, 2015, 20 (10) :18759-18776